Global Cannabinoid Drugs Market

Cannabinoid Drugs Comprehensive Study by Type (Phytocannabinoids, Endocannabinoids, Synthetics), Application (Chronic Diseases, Anxiety, Nausea, Others), End-users (Hospitals, Clinics, Ambulatory Surgical Centers, Others), Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies) Players and Region - Global Market Outlook to 2027

Cannabinoid Drugs Market by XX Submarkets | Forecast Years 2022-2027  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
What is Cannabinoid Drugs Market?

Cannabinoids drugs are drugs that share active agents found in Cannabis (Marijuana) or were synthetically developed from those drugs. The cannabis plant produces between 80 and 100 cannabinoids and about 300 non-cannabinoid chemicals. The cannabinoid derived from hemp plants are legal and can be found in many markets. The use of cannabinoid drugs is currently legal for medical purposes in 30 states and the District of Columbia. The physicians are increasingly prescribing these drugs for medical reasons such as relieving pain in cancer patients.

The market study is being classified by Type (Phytocannabinoids, Endocannabinoids and Synthetics), by Application (Chronic Diseases, Anxiety, Nausea and Others) and major geographies with country level break-up.

Echo Pharmaceuticals B.V. (Netherlands), Mandara Pharma (Canada), GW Pharmaceuticals, plc (United Kingdom), Nexien BioPharma (United States), BOL Pharma (Israel), CURE Pharmaceutical Holding Corp. (United States), RAMM Pharma (Canada), Greenwich Biosciences, Inc. (United States), UNIVO Pharmaceuticals (Israel), InMed Pharmaceuticals (Canada) and Abbott Laboratories (United States) are some of the key players profiled in the study. Additionally, the Players which are also part of the research are Ilesol Pharmaceuticals d.o.o. (Croatia), Valeant Pharmaceuticals International (Canada) and Indevus Pharmaceuticals Inc. (United States).

The companies are exploring the market by adopting expansions, investments, new service launches and collaborations as their preferred strategies. The players are exploring new geographies through expansions and acquisitions across the globe to gain a competitive advantage through combined collaborations. Research Analyst at AMA predicts that United States Players will contribute to the maximum growth of Global Cannabinoid Drugs market throughout the predicted period.

Segment Analysis
Analyst at AMA have segmented the market study of Global Cannabinoid Drugs market by Type, Application and Region.

On the basis of geography, the market of Cannabinoid Drugs has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth.

Market Drivers
  • Increasing Prevalence of Chronic Diseases
  • Increased Legalization of Cannabinoid

Market Trend
  • Increased Research and Development Activities on Cannabinoid Drugs Applications

Restraints
  • Side Effects of the Cannabinoid Drugs
  • Limited Applications of Cannabinoid Drugs

Opportunities
  • Huge Investment by Major Players
  • Growing Number of Geriatric Population

Challenges
  • Stringent Government Rules and Regulations


Market Leaders and some development strategies
In June 2020, GW Pharmaceuticals plc, a world leader in discovering, developing and delivering regulatory approved cannabis-based medicines, has announced that the UK Home Office has reclassified EPIDYOLEX (cannabidiol) as a Schedule 5 drug.



Key Target Audience
Cannabinoid Drugs Manufacturers, Raw Material Suppliers, Distributors, Emerging Companies and End-users

Report Objectives / Segmentation Covered

By Type
  • Phytocannabinoids
  • Endocannabinoids
  • Synthetics
By Application
  • Chronic Diseases
  • Anxiety
  • Nausea
  • Others
By End-users
  • Hospitals
  • Clinics
  • Ambulatory Surgical Centers
  • Others

By Distribution Channel
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Increasing Prevalence of Chronic Diseases
      • 3.2.2. Increased Legalization of Cannabinoid
    • 3.3. Market Challenges
      • 3.3.1. Stringent Government Rules and Regulations
    • 3.4. Market Trends
      • 3.4.1. Increased Research and Development Activities on Cannabinoid Drugs Applications
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Cannabinoid Drugs, by Type, Application, End-users, Distribution Channel and Region (value, volume and price ) (2016-2021)
    • 5.1. Introduction
    • 5.2. Global Cannabinoid Drugs (Value)
      • 5.2.1. Global Cannabinoid Drugs by: Type (Value)
        • 5.2.1.1. Phytocannabinoids
        • 5.2.1.2. Endocannabinoids
        • 5.2.1.3. Synthetics
      • 5.2.2. Global Cannabinoid Drugs by: Application (Value)
        • 5.2.2.1. Chronic Diseases
        • 5.2.2.2. Anxiety
        • 5.2.2.3. Nausea
        • 5.2.2.4. Others
      • 5.2.3. Global Cannabinoid Drugs by: End-users (Value)
        • 5.2.3.1. Hospitals
        • 5.2.3.2. Clinics
        • 5.2.3.3. Ambulatory Surgical Centers
        • 5.2.3.4. Others
      • 5.2.4. Global Cannabinoid Drugs by: Distribution Channel (Value)
        • 5.2.4.1. Hospital Pharmacies
        • 5.2.4.2. Retail Pharmacies
        • 5.2.4.3. Online Pharmacies
      • 5.2.5. Global Cannabinoid Drugs Region
        • 5.2.5.1. South America
          • 5.2.5.1.1. Brazil
          • 5.2.5.1.2. Argentina
          • 5.2.5.1.3. Rest of South America
        • 5.2.5.2. Asia Pacific
          • 5.2.5.2.1. China
          • 5.2.5.2.2. Japan
          • 5.2.5.2.3. India
          • 5.2.5.2.4. South Korea
          • 5.2.5.2.5. Taiwan
          • 5.2.5.2.6. Australia
          • 5.2.5.2.7. Rest of Asia-Pacific
        • 5.2.5.3. Europe
          • 5.2.5.3.1. Germany
          • 5.2.5.3.2. France
          • 5.2.5.3.3. Italy
          • 5.2.5.3.4. United Kingdom
          • 5.2.5.3.5. Netherlands
          • 5.2.5.3.6. Rest of Europe
        • 5.2.5.4. MEA
          • 5.2.5.4.1. Middle East
          • 5.2.5.4.2. Africa
        • 5.2.5.5. North America
          • 5.2.5.5.1. United States
          • 5.2.5.5.2. Canada
          • 5.2.5.5.3. Mexico
    • 5.3. Global Cannabinoid Drugs (Volume)
      • 5.3.1. Global Cannabinoid Drugs by: Type (Volume)
        • 5.3.1.1. Phytocannabinoids
        • 5.3.1.2. Endocannabinoids
        • 5.3.1.3. Synthetics
      • 5.3.2. Global Cannabinoid Drugs by: Application (Volume)
        • 5.3.2.1. Chronic Diseases
        • 5.3.2.2. Anxiety
        • 5.3.2.3. Nausea
        • 5.3.2.4. Others
      • 5.3.3. Global Cannabinoid Drugs by: End-users (Volume)
        • 5.3.3.1. Hospitals
        • 5.3.3.2. Clinics
        • 5.3.3.3. Ambulatory Surgical Centers
        • 5.3.3.4. Others
      • 5.3.4. Global Cannabinoid Drugs by: Distribution Channel (Volume)
        • 5.3.4.1. Hospital Pharmacies
        • 5.3.4.2. Retail Pharmacies
        • 5.3.4.3. Online Pharmacies
      • 5.3.5. Global Cannabinoid Drugs Region
        • 5.3.5.1. South America
          • 5.3.5.1.1. Brazil
          • 5.3.5.1.2. Argentina
          • 5.3.5.1.3. Rest of South America
        • 5.3.5.2. Asia Pacific
          • 5.3.5.2.1. China
          • 5.3.5.2.2. Japan
          • 5.3.5.2.3. India
          • 5.3.5.2.4. South Korea
          • 5.3.5.2.5. Taiwan
          • 5.3.5.2.6. Australia
          • 5.3.5.2.7. Rest of Asia-Pacific
        • 5.3.5.3. Europe
          • 5.3.5.3.1. Germany
          • 5.3.5.3.2. France
          • 5.3.5.3.3. Italy
          • 5.3.5.3.4. United Kingdom
          • 5.3.5.3.5. Netherlands
          • 5.3.5.3.6. Rest of Europe
        • 5.3.5.4. MEA
          • 5.3.5.4.1. Middle East
          • 5.3.5.4.2. Africa
        • 5.3.5.5. North America
          • 5.3.5.5.1. United States
          • 5.3.5.5.2. Canada
          • 5.3.5.5.3. Mexico
    • 5.4. Global Cannabinoid Drugs (Price)
      • 5.4.1. Global Cannabinoid Drugs by: Type (Price)
  • 6. Cannabinoid Drugs: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2021)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Echo Pharmaceuticals B.V. (Netherlands)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Mandara Pharma (Canada)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. GW Pharmaceuticals, plc (United Kingdom)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Nexien BioPharma (United States)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. BOL Pharma (Israel)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. CURE Pharmaceutical Holding Corp. (United States)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. RAMM Pharma (Canada)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Greenwich Biosciences, Inc. (United States)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. UNIVO Pharmaceuticals (Israel)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. InMed Pharmaceuticals (Canada)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
      • 6.4.11. Abbott Laboratories (United States)
        • 6.4.11.1. Business Overview
        • 6.4.11.2. Products/Services Offerings
        • 6.4.11.3. Financial Analysis
        • 6.4.11.4. SWOT Analysis
  • 7. Global Cannabinoid Drugs Sale, by Type, Application, End-users, Distribution Channel and Region (value, volume and price ) (2022-2027)
    • 7.1. Introduction
    • 7.2. Global Cannabinoid Drugs (Value)
      • 7.2.1. Global Cannabinoid Drugs by: Type (Value)
        • 7.2.1.1. Phytocannabinoids
        • 7.2.1.2. Endocannabinoids
        • 7.2.1.3. Synthetics
      • 7.2.2. Global Cannabinoid Drugs by: Application (Value)
        • 7.2.2.1. Chronic Diseases
        • 7.2.2.2. Anxiety
        • 7.2.2.3. Nausea
        • 7.2.2.4. Others
      • 7.2.3. Global Cannabinoid Drugs by: End-users (Value)
        • 7.2.3.1. Hospitals
        • 7.2.3.2. Clinics
        • 7.2.3.3. Ambulatory Surgical Centers
        • 7.2.3.4. Others
      • 7.2.4. Global Cannabinoid Drugs by: Distribution Channel (Value)
        • 7.2.4.1. Hospital Pharmacies
        • 7.2.4.2. Retail Pharmacies
        • 7.2.4.3. Online Pharmacies
      • 7.2.5. Global Cannabinoid Drugs Region
        • 7.2.5.1. South America
          • 7.2.5.1.1. Brazil
          • 7.2.5.1.2. Argentina
          • 7.2.5.1.3. Rest of South America
        • 7.2.5.2. Asia Pacific
          • 7.2.5.2.1. China
          • 7.2.5.2.2. Japan
          • 7.2.5.2.3. India
          • 7.2.5.2.4. South Korea
          • 7.2.5.2.5. Taiwan
          • 7.2.5.2.6. Australia
          • 7.2.5.2.7. Rest of Asia-Pacific
        • 7.2.5.3. Europe
          • 7.2.5.3.1. Germany
          • 7.2.5.3.2. France
          • 7.2.5.3.3. Italy
          • 7.2.5.3.4. United Kingdom
          • 7.2.5.3.5. Netherlands
          • 7.2.5.3.6. Rest of Europe
        • 7.2.5.4. MEA
          • 7.2.5.4.1. Middle East
          • 7.2.5.4.2. Africa
        • 7.2.5.5. North America
          • 7.2.5.5.1. United States
          • 7.2.5.5.2. Canada
          • 7.2.5.5.3. Mexico
    • 7.3. Global Cannabinoid Drugs (Volume)
      • 7.3.1. Global Cannabinoid Drugs by: Type (Volume)
        • 7.3.1.1. Phytocannabinoids
        • 7.3.1.2. Endocannabinoids
        • 7.3.1.3. Synthetics
      • 7.3.2. Global Cannabinoid Drugs by: Application (Volume)
        • 7.3.2.1. Chronic Diseases
        • 7.3.2.2. Anxiety
        • 7.3.2.3. Nausea
        • 7.3.2.4. Others
      • 7.3.3. Global Cannabinoid Drugs by: End-users (Volume)
        • 7.3.3.1. Hospitals
        • 7.3.3.2. Clinics
        • 7.3.3.3. Ambulatory Surgical Centers
        • 7.3.3.4. Others
      • 7.3.4. Global Cannabinoid Drugs by: Distribution Channel (Volume)
        • 7.3.4.1. Hospital Pharmacies
        • 7.3.4.2. Retail Pharmacies
        • 7.3.4.3. Online Pharmacies
      • 7.3.5. Global Cannabinoid Drugs Region
        • 7.3.5.1. South America
          • 7.3.5.1.1. Brazil
          • 7.3.5.1.2. Argentina
          • 7.3.5.1.3. Rest of South America
        • 7.3.5.2. Asia Pacific
          • 7.3.5.2.1. China
          • 7.3.5.2.2. Japan
          • 7.3.5.2.3. India
          • 7.3.5.2.4. South Korea
          • 7.3.5.2.5. Taiwan
          • 7.3.5.2.6. Australia
          • 7.3.5.2.7. Rest of Asia-Pacific
        • 7.3.5.3. Europe
          • 7.3.5.3.1. Germany
          • 7.3.5.3.2. France
          • 7.3.5.3.3. Italy
          • 7.3.5.3.4. United Kingdom
          • 7.3.5.3.5. Netherlands
          • 7.3.5.3.6. Rest of Europe
        • 7.3.5.4. MEA
          • 7.3.5.4.1. Middle East
          • 7.3.5.4.2. Africa
        • 7.3.5.5. North America
          • 7.3.5.5.1. United States
          • 7.3.5.5.2. Canada
          • 7.3.5.5.3. Mexico
    • 7.4. Global Cannabinoid Drugs (Price)
      • 7.4.1. Global Cannabinoid Drugs by: Type (Price)
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Cannabinoid Drugs: by Type(USD Million)
  • Table 2. Cannabinoid Drugs Phytocannabinoids , by Region USD Million (2016-2021)
  • Table 3. Cannabinoid Drugs Endocannabinoids , by Region USD Million (2016-2021)
  • Table 4. Cannabinoid Drugs Synthetics , by Region USD Million (2016-2021)
  • Table 5. Cannabinoid Drugs: by Application(USD Million)
  • Table 6. Cannabinoid Drugs Chronic Diseases , by Region USD Million (2016-2021)
  • Table 7. Cannabinoid Drugs Anxiety , by Region USD Million (2016-2021)
  • Table 8. Cannabinoid Drugs Nausea , by Region USD Million (2016-2021)
  • Table 9. Cannabinoid Drugs Others , by Region USD Million (2016-2021)
  • Table 10. Cannabinoid Drugs: by End-users(USD Million)
  • Table 11. Cannabinoid Drugs Hospitals , by Region USD Million (2016-2021)
  • Table 12. Cannabinoid Drugs Clinics , by Region USD Million (2016-2021)
  • Table 13. Cannabinoid Drugs Ambulatory Surgical Centers , by Region USD Million (2016-2021)
  • Table 14. Cannabinoid Drugs Others , by Region USD Million (2016-2021)
  • Table 15. Cannabinoid Drugs: by Distribution Channel(USD Million)
  • Table 16. Cannabinoid Drugs Hospital Pharmacies , by Region USD Million (2016-2021)
  • Table 17. Cannabinoid Drugs Retail Pharmacies , by Region USD Million (2016-2021)
  • Table 18. Cannabinoid Drugs Online Pharmacies , by Region USD Million (2016-2021)
  • Table 19. South America Cannabinoid Drugs, by Country USD Million (2016-2021)
  • Table 20. South America Cannabinoid Drugs, by Type USD Million (2016-2021)
  • Table 21. South America Cannabinoid Drugs, by Application USD Million (2016-2021)
  • Table 22. South America Cannabinoid Drugs, by End-users USD Million (2016-2021)
  • Table 23. South America Cannabinoid Drugs, by Distribution Channel USD Million (2016-2021)
  • Table 24. Brazil Cannabinoid Drugs, by Type USD Million (2016-2021)
  • Table 25. Brazil Cannabinoid Drugs, by Application USD Million (2016-2021)
  • Table 26. Brazil Cannabinoid Drugs, by End-users USD Million (2016-2021)
  • Table 27. Brazil Cannabinoid Drugs, by Distribution Channel USD Million (2016-2021)
  • Table 28. Argentina Cannabinoid Drugs, by Type USD Million (2016-2021)
  • Table 29. Argentina Cannabinoid Drugs, by Application USD Million (2016-2021)
  • Table 30. Argentina Cannabinoid Drugs, by End-users USD Million (2016-2021)
  • Table 31. Argentina Cannabinoid Drugs, by Distribution Channel USD Million (2016-2021)
  • Table 32. Rest of South America Cannabinoid Drugs, by Type USD Million (2016-2021)
  • Table 33. Rest of South America Cannabinoid Drugs, by Application USD Million (2016-2021)
  • Table 34. Rest of South America Cannabinoid Drugs, by End-users USD Million (2016-2021)
  • Table 35. Rest of South America Cannabinoid Drugs, by Distribution Channel USD Million (2016-2021)
  • Table 36. Asia Pacific Cannabinoid Drugs, by Country USD Million (2016-2021)
  • Table 37. Asia Pacific Cannabinoid Drugs, by Type USD Million (2016-2021)
  • Table 38. Asia Pacific Cannabinoid Drugs, by Application USD Million (2016-2021)
  • Table 39. Asia Pacific Cannabinoid Drugs, by End-users USD Million (2016-2021)
  • Table 40. Asia Pacific Cannabinoid Drugs, by Distribution Channel USD Million (2016-2021)
  • Table 41. China Cannabinoid Drugs, by Type USD Million (2016-2021)
  • Table 42. China Cannabinoid Drugs, by Application USD Million (2016-2021)
  • Table 43. China Cannabinoid Drugs, by End-users USD Million (2016-2021)
  • Table 44. China Cannabinoid Drugs, by Distribution Channel USD Million (2016-2021)
  • Table 45. Japan Cannabinoid Drugs, by Type USD Million (2016-2021)
  • Table 46. Japan Cannabinoid Drugs, by Application USD Million (2016-2021)
  • Table 47. Japan Cannabinoid Drugs, by End-users USD Million (2016-2021)
  • Table 48. Japan Cannabinoid Drugs, by Distribution Channel USD Million (2016-2021)
  • Table 49. India Cannabinoid Drugs, by Type USD Million (2016-2021)
  • Table 50. India Cannabinoid Drugs, by Application USD Million (2016-2021)
  • Table 51. India Cannabinoid Drugs, by End-users USD Million (2016-2021)
  • Table 52. India Cannabinoid Drugs, by Distribution Channel USD Million (2016-2021)
  • Table 53. South Korea Cannabinoid Drugs, by Type USD Million (2016-2021)
  • Table 54. South Korea Cannabinoid Drugs, by Application USD Million (2016-2021)
  • Table 55. South Korea Cannabinoid Drugs, by End-users USD Million (2016-2021)
  • Table 56. South Korea Cannabinoid Drugs, by Distribution Channel USD Million (2016-2021)
  • Table 57. Taiwan Cannabinoid Drugs, by Type USD Million (2016-2021)
  • Table 58. Taiwan Cannabinoid Drugs, by Application USD Million (2016-2021)
  • Table 59. Taiwan Cannabinoid Drugs, by End-users USD Million (2016-2021)
  • Table 60. Taiwan Cannabinoid Drugs, by Distribution Channel USD Million (2016-2021)
  • Table 61. Australia Cannabinoid Drugs, by Type USD Million (2016-2021)
  • Table 62. Australia Cannabinoid Drugs, by Application USD Million (2016-2021)
  • Table 63. Australia Cannabinoid Drugs, by End-users USD Million (2016-2021)
  • Table 64. Australia Cannabinoid Drugs, by Distribution Channel USD Million (2016-2021)
  • Table 65. Rest of Asia-Pacific Cannabinoid Drugs, by Type USD Million (2016-2021)
  • Table 66. Rest of Asia-Pacific Cannabinoid Drugs, by Application USD Million (2016-2021)
  • Table 67. Rest of Asia-Pacific Cannabinoid Drugs, by End-users USD Million (2016-2021)
  • Table 68. Rest of Asia-Pacific Cannabinoid Drugs, by Distribution Channel USD Million (2016-2021)
  • Table 69. Europe Cannabinoid Drugs, by Country USD Million (2016-2021)
  • Table 70. Europe Cannabinoid Drugs, by Type USD Million (2016-2021)
  • Table 71. Europe Cannabinoid Drugs, by Application USD Million (2016-2021)
  • Table 72. Europe Cannabinoid Drugs, by End-users USD Million (2016-2021)
  • Table 73. Europe Cannabinoid Drugs, by Distribution Channel USD Million (2016-2021)
  • Table 74. Germany Cannabinoid Drugs, by Type USD Million (2016-2021)
  • Table 75. Germany Cannabinoid Drugs, by Application USD Million (2016-2021)
  • Table 76. Germany Cannabinoid Drugs, by End-users USD Million (2016-2021)
  • Table 77. Germany Cannabinoid Drugs, by Distribution Channel USD Million (2016-2021)
  • Table 78. France Cannabinoid Drugs, by Type USD Million (2016-2021)
  • Table 79. France Cannabinoid Drugs, by Application USD Million (2016-2021)
  • Table 80. France Cannabinoid Drugs, by End-users USD Million (2016-2021)
  • Table 81. France Cannabinoid Drugs, by Distribution Channel USD Million (2016-2021)
  • Table 82. Italy Cannabinoid Drugs, by Type USD Million (2016-2021)
  • Table 83. Italy Cannabinoid Drugs, by Application USD Million (2016-2021)
  • Table 84. Italy Cannabinoid Drugs, by End-users USD Million (2016-2021)
  • Table 85. Italy Cannabinoid Drugs, by Distribution Channel USD Million (2016-2021)
  • Table 86. United Kingdom Cannabinoid Drugs, by Type USD Million (2016-2021)
  • Table 87. United Kingdom Cannabinoid Drugs, by Application USD Million (2016-2021)
  • Table 88. United Kingdom Cannabinoid Drugs, by End-users USD Million (2016-2021)
  • Table 89. United Kingdom Cannabinoid Drugs, by Distribution Channel USD Million (2016-2021)
  • Table 90. Netherlands Cannabinoid Drugs, by Type USD Million (2016-2021)
  • Table 91. Netherlands Cannabinoid Drugs, by Application USD Million (2016-2021)
  • Table 92. Netherlands Cannabinoid Drugs, by End-users USD Million (2016-2021)
  • Table 93. Netherlands Cannabinoid Drugs, by Distribution Channel USD Million (2016-2021)
  • Table 94. Rest of Europe Cannabinoid Drugs, by Type USD Million (2016-2021)
  • Table 95. Rest of Europe Cannabinoid Drugs, by Application USD Million (2016-2021)
  • Table 96. Rest of Europe Cannabinoid Drugs, by End-users USD Million (2016-2021)
  • Table 97. Rest of Europe Cannabinoid Drugs, by Distribution Channel USD Million (2016-2021)
  • Table 98. MEA Cannabinoid Drugs, by Country USD Million (2016-2021)
  • Table 99. MEA Cannabinoid Drugs, by Type USD Million (2016-2021)
  • Table 100. MEA Cannabinoid Drugs, by Application USD Million (2016-2021)
  • Table 101. MEA Cannabinoid Drugs, by End-users USD Million (2016-2021)
  • Table 102. MEA Cannabinoid Drugs, by Distribution Channel USD Million (2016-2021)
  • Table 103. Middle East Cannabinoid Drugs, by Type USD Million (2016-2021)
  • Table 104. Middle East Cannabinoid Drugs, by Application USD Million (2016-2021)
  • Table 105. Middle East Cannabinoid Drugs, by End-users USD Million (2016-2021)
  • Table 106. Middle East Cannabinoid Drugs, by Distribution Channel USD Million (2016-2021)
  • Table 107. Africa Cannabinoid Drugs, by Type USD Million (2016-2021)
  • Table 108. Africa Cannabinoid Drugs, by Application USD Million (2016-2021)
  • Table 109. Africa Cannabinoid Drugs, by End-users USD Million (2016-2021)
  • Table 110. Africa Cannabinoid Drugs, by Distribution Channel USD Million (2016-2021)
  • Table 111. North America Cannabinoid Drugs, by Country USD Million (2016-2021)
  • Table 112. North America Cannabinoid Drugs, by Type USD Million (2016-2021)
  • Table 113. North America Cannabinoid Drugs, by Application USD Million (2016-2021)
  • Table 114. North America Cannabinoid Drugs, by End-users USD Million (2016-2021)
  • Table 115. North America Cannabinoid Drugs, by Distribution Channel USD Million (2016-2021)
  • Table 116. United States Cannabinoid Drugs, by Type USD Million (2016-2021)
  • Table 117. United States Cannabinoid Drugs, by Application USD Million (2016-2021)
  • Table 118. United States Cannabinoid Drugs, by End-users USD Million (2016-2021)
  • Table 119. United States Cannabinoid Drugs, by Distribution Channel USD Million (2016-2021)
  • Table 120. Canada Cannabinoid Drugs, by Type USD Million (2016-2021)
  • Table 121. Canada Cannabinoid Drugs, by Application USD Million (2016-2021)
  • Table 122. Canada Cannabinoid Drugs, by End-users USD Million (2016-2021)
  • Table 123. Canada Cannabinoid Drugs, by Distribution Channel USD Million (2016-2021)
  • Table 124. Mexico Cannabinoid Drugs, by Type USD Million (2016-2021)
  • Table 125. Mexico Cannabinoid Drugs, by Application USD Million (2016-2021)
  • Table 126. Mexico Cannabinoid Drugs, by End-users USD Million (2016-2021)
  • Table 127. Mexico Cannabinoid Drugs, by Distribution Channel USD Million (2016-2021)
  • Table 128. Cannabinoid Drugs Sales: by Type(K Units)
  • Table 129. Cannabinoid Drugs Sales Phytocannabinoids , by Region K Units (2016-2021)
  • Table 130. Cannabinoid Drugs Sales Endocannabinoids , by Region K Units (2016-2021)
  • Table 131. Cannabinoid Drugs Sales Synthetics , by Region K Units (2016-2021)
  • Table 132. Cannabinoid Drugs Sales: by Application(K Units)
  • Table 133. Cannabinoid Drugs Sales Chronic Diseases , by Region K Units (2016-2021)
  • Table 134. Cannabinoid Drugs Sales Anxiety , by Region K Units (2016-2021)
  • Table 135. Cannabinoid Drugs Sales Nausea , by Region K Units (2016-2021)
  • Table 136. Cannabinoid Drugs Sales Others , by Region K Units (2016-2021)
  • Table 137. Cannabinoid Drugs Sales: by End-users(K Units)
  • Table 138. Cannabinoid Drugs Sales Hospitals , by Region K Units (2016-2021)
  • Table 139. Cannabinoid Drugs Sales Clinics , by Region K Units (2016-2021)
  • Table 140. Cannabinoid Drugs Sales Ambulatory Surgical Centers , by Region K Units (2016-2021)
  • Table 141. Cannabinoid Drugs Sales Others , by Region K Units (2016-2021)
  • Table 142. Cannabinoid Drugs Sales: by Distribution Channel(K Units)
  • Table 143. Cannabinoid Drugs Sales Hospital Pharmacies , by Region K Units (2016-2021)
  • Table 144. Cannabinoid Drugs Sales Retail Pharmacies , by Region K Units (2016-2021)
  • Table 145. Cannabinoid Drugs Sales Online Pharmacies , by Region K Units (2016-2021)
  • Table 146. South America Cannabinoid Drugs Sales, by Country K Units (2016-2021)
  • Table 147. South America Cannabinoid Drugs Sales, by Type K Units (2016-2021)
  • Table 148. South America Cannabinoid Drugs Sales, by Application K Units (2016-2021)
  • Table 149. South America Cannabinoid Drugs Sales, by End-users K Units (2016-2021)
  • Table 150. South America Cannabinoid Drugs Sales, by Distribution Channel K Units (2016-2021)
  • Table 151. Brazil Cannabinoid Drugs Sales, by Type K Units (2016-2021)
  • Table 152. Brazil Cannabinoid Drugs Sales, by Application K Units (2016-2021)
  • Table 153. Brazil Cannabinoid Drugs Sales, by End-users K Units (2016-2021)
  • Table 154. Brazil Cannabinoid Drugs Sales, by Distribution Channel K Units (2016-2021)
  • Table 155. Argentina Cannabinoid Drugs Sales, by Type K Units (2016-2021)
  • Table 156. Argentina Cannabinoid Drugs Sales, by Application K Units (2016-2021)
  • Table 157. Argentina Cannabinoid Drugs Sales, by End-users K Units (2016-2021)
  • Table 158. Argentina Cannabinoid Drugs Sales, by Distribution Channel K Units (2016-2021)
  • Table 159. Rest of South America Cannabinoid Drugs Sales, by Type K Units (2016-2021)
  • Table 160. Rest of South America Cannabinoid Drugs Sales, by Application K Units (2016-2021)
  • Table 161. Rest of South America Cannabinoid Drugs Sales, by End-users K Units (2016-2021)
  • Table 162. Rest of South America Cannabinoid Drugs Sales, by Distribution Channel K Units (2016-2021)
  • Table 163. Asia Pacific Cannabinoid Drugs Sales, by Country K Units (2016-2021)
  • Table 164. Asia Pacific Cannabinoid Drugs Sales, by Type K Units (2016-2021)
  • Table 165. Asia Pacific Cannabinoid Drugs Sales, by Application K Units (2016-2021)
  • Table 166. Asia Pacific Cannabinoid Drugs Sales, by End-users K Units (2016-2021)
  • Table 167. Asia Pacific Cannabinoid Drugs Sales, by Distribution Channel K Units (2016-2021)
  • Table 168. China Cannabinoid Drugs Sales, by Type K Units (2016-2021)
  • Table 169. China Cannabinoid Drugs Sales, by Application K Units (2016-2021)
  • Table 170. China Cannabinoid Drugs Sales, by End-users K Units (2016-2021)
  • Table 171. China Cannabinoid Drugs Sales, by Distribution Channel K Units (2016-2021)
  • Table 172. Japan Cannabinoid Drugs Sales, by Type K Units (2016-2021)
  • Table 173. Japan Cannabinoid Drugs Sales, by Application K Units (2016-2021)
  • Table 174. Japan Cannabinoid Drugs Sales, by End-users K Units (2016-2021)
  • Table 175. Japan Cannabinoid Drugs Sales, by Distribution Channel K Units (2016-2021)
  • Table 176. India Cannabinoid Drugs Sales, by Type K Units (2016-2021)
  • Table 177. India Cannabinoid Drugs Sales, by Application K Units (2016-2021)
  • Table 178. India Cannabinoid Drugs Sales, by End-users K Units (2016-2021)
  • Table 179. India Cannabinoid Drugs Sales, by Distribution Channel K Units (2016-2021)
  • Table 180. South Korea Cannabinoid Drugs Sales, by Type K Units (2016-2021)
  • Table 181. South Korea Cannabinoid Drugs Sales, by Application K Units (2016-2021)
  • Table 182. South Korea Cannabinoid Drugs Sales, by End-users K Units (2016-2021)
  • Table 183. South Korea Cannabinoid Drugs Sales, by Distribution Channel K Units (2016-2021)
  • Table 184. Taiwan Cannabinoid Drugs Sales, by Type K Units (2016-2021)
  • Table 185. Taiwan Cannabinoid Drugs Sales, by Application K Units (2016-2021)
  • Table 186. Taiwan Cannabinoid Drugs Sales, by End-users K Units (2016-2021)
  • Table 187. Taiwan Cannabinoid Drugs Sales, by Distribution Channel K Units (2016-2021)
  • Table 188. Australia Cannabinoid Drugs Sales, by Type K Units (2016-2021)
  • Table 189. Australia Cannabinoid Drugs Sales, by Application K Units (2016-2021)
  • Table 190. Australia Cannabinoid Drugs Sales, by End-users K Units (2016-2021)
  • Table 191. Australia Cannabinoid Drugs Sales, by Distribution Channel K Units (2016-2021)
  • Table 192. Rest of Asia-Pacific Cannabinoid Drugs Sales, by Type K Units (2016-2021)
  • Table 193. Rest of Asia-Pacific Cannabinoid Drugs Sales, by Application K Units (2016-2021)
  • Table 194. Rest of Asia-Pacific Cannabinoid Drugs Sales, by End-users K Units (2016-2021)
  • Table 195. Rest of Asia-Pacific Cannabinoid Drugs Sales, by Distribution Channel K Units (2016-2021)
  • Table 196. Europe Cannabinoid Drugs Sales, by Country K Units (2016-2021)
  • Table 197. Europe Cannabinoid Drugs Sales, by Type K Units (2016-2021)
  • Table 198. Europe Cannabinoid Drugs Sales, by Application K Units (2016-2021)
  • Table 199. Europe Cannabinoid Drugs Sales, by End-users K Units (2016-2021)
  • Table 200. Europe Cannabinoid Drugs Sales, by Distribution Channel K Units (2016-2021)
  • Table 201. Germany Cannabinoid Drugs Sales, by Type K Units (2016-2021)
  • Table 202. Germany Cannabinoid Drugs Sales, by Application K Units (2016-2021)
  • Table 203. Germany Cannabinoid Drugs Sales, by End-users K Units (2016-2021)
  • Table 204. Germany Cannabinoid Drugs Sales, by Distribution Channel K Units (2016-2021)
  • Table 205. France Cannabinoid Drugs Sales, by Type K Units (2016-2021)
  • Table 206. France Cannabinoid Drugs Sales, by Application K Units (2016-2021)
  • Table 207. France Cannabinoid Drugs Sales, by End-users K Units (2016-2021)
  • Table 208. France Cannabinoid Drugs Sales, by Distribution Channel K Units (2016-2021)
  • Table 209. Italy Cannabinoid Drugs Sales, by Type K Units (2016-2021)
  • Table 210. Italy Cannabinoid Drugs Sales, by Application K Units (2016-2021)
  • Table 211. Italy Cannabinoid Drugs Sales, by End-users K Units (2016-2021)
  • Table 212. Italy Cannabinoid Drugs Sales, by Distribution Channel K Units (2016-2021)
  • Table 213. United Kingdom Cannabinoid Drugs Sales, by Type K Units (2016-2021)
  • Table 214. United Kingdom Cannabinoid Drugs Sales, by Application K Units (2016-2021)
  • Table 215. United Kingdom Cannabinoid Drugs Sales, by End-users K Units (2016-2021)
  • Table 216. United Kingdom Cannabinoid Drugs Sales, by Distribution Channel K Units (2016-2021)
  • Table 217. Netherlands Cannabinoid Drugs Sales, by Type K Units (2016-2021)
  • Table 218. Netherlands Cannabinoid Drugs Sales, by Application K Units (2016-2021)
  • Table 219. Netherlands Cannabinoid Drugs Sales, by End-users K Units (2016-2021)
  • Table 220. Netherlands Cannabinoid Drugs Sales, by Distribution Channel K Units (2016-2021)
  • Table 221. Rest of Europe Cannabinoid Drugs Sales, by Type K Units (2016-2021)
  • Table 222. Rest of Europe Cannabinoid Drugs Sales, by Application K Units (2016-2021)
  • Table 223. Rest of Europe Cannabinoid Drugs Sales, by End-users K Units (2016-2021)
  • Table 224. Rest of Europe Cannabinoid Drugs Sales, by Distribution Channel K Units (2016-2021)
  • Table 225. MEA Cannabinoid Drugs Sales, by Country K Units (2016-2021)
  • Table 226. MEA Cannabinoid Drugs Sales, by Type K Units (2016-2021)
  • Table 227. MEA Cannabinoid Drugs Sales, by Application K Units (2016-2021)
  • Table 228. MEA Cannabinoid Drugs Sales, by End-users K Units (2016-2021)
  • Table 229. MEA Cannabinoid Drugs Sales, by Distribution Channel K Units (2016-2021)
  • Table 230. Middle East Cannabinoid Drugs Sales, by Type K Units (2016-2021)
  • Table 231. Middle East Cannabinoid Drugs Sales, by Application K Units (2016-2021)
  • Table 232. Middle East Cannabinoid Drugs Sales, by End-users K Units (2016-2021)
  • Table 233. Middle East Cannabinoid Drugs Sales, by Distribution Channel K Units (2016-2021)
  • Table 234. Africa Cannabinoid Drugs Sales, by Type K Units (2016-2021)
  • Table 235. Africa Cannabinoid Drugs Sales, by Application K Units (2016-2021)
  • Table 236. Africa Cannabinoid Drugs Sales, by End-users K Units (2016-2021)
  • Table 237. Africa Cannabinoid Drugs Sales, by Distribution Channel K Units (2016-2021)
  • Table 238. North America Cannabinoid Drugs Sales, by Country K Units (2016-2021)
  • Table 239. North America Cannabinoid Drugs Sales, by Type K Units (2016-2021)
  • Table 240. North America Cannabinoid Drugs Sales, by Application K Units (2016-2021)
  • Table 241. North America Cannabinoid Drugs Sales, by End-users K Units (2016-2021)
  • Table 242. North America Cannabinoid Drugs Sales, by Distribution Channel K Units (2016-2021)
  • Table 243. United States Cannabinoid Drugs Sales, by Type K Units (2016-2021)
  • Table 244. United States Cannabinoid Drugs Sales, by Application K Units (2016-2021)
  • Table 245. United States Cannabinoid Drugs Sales, by End-users K Units (2016-2021)
  • Table 246. United States Cannabinoid Drugs Sales, by Distribution Channel K Units (2016-2021)
  • Table 247. Canada Cannabinoid Drugs Sales, by Type K Units (2016-2021)
  • Table 248. Canada Cannabinoid Drugs Sales, by Application K Units (2016-2021)
  • Table 249. Canada Cannabinoid Drugs Sales, by End-users K Units (2016-2021)
  • Table 250. Canada Cannabinoid Drugs Sales, by Distribution Channel K Units (2016-2021)
  • Table 251. Mexico Cannabinoid Drugs Sales, by Type K Units (2016-2021)
  • Table 252. Mexico Cannabinoid Drugs Sales, by Application K Units (2016-2021)
  • Table 253. Mexico Cannabinoid Drugs Sales, by End-users K Units (2016-2021)
  • Table 254. Mexico Cannabinoid Drugs Sales, by Distribution Channel K Units (2016-2021)
  • Table 255. Cannabinoid Drugs: by Type(USD/Units)
  • Table 256. Company Basic Information, Sales Area and Its Competitors
  • Table 257. Company Basic Information, Sales Area and Its Competitors
  • Table 258. Company Basic Information, Sales Area and Its Competitors
  • Table 259. Company Basic Information, Sales Area and Its Competitors
  • Table 260. Company Basic Information, Sales Area and Its Competitors
  • Table 261. Company Basic Information, Sales Area and Its Competitors
  • Table 262. Company Basic Information, Sales Area and Its Competitors
  • Table 263. Company Basic Information, Sales Area and Its Competitors
  • Table 264. Company Basic Information, Sales Area and Its Competitors
  • Table 265. Company Basic Information, Sales Area and Its Competitors
  • Table 266. Company Basic Information, Sales Area and Its Competitors
  • Table 267. Cannabinoid Drugs: by Type(USD Million)
  • Table 268. Cannabinoid Drugs Phytocannabinoids , by Region USD Million (2022-2027)
  • Table 269. Cannabinoid Drugs Endocannabinoids , by Region USD Million (2022-2027)
  • Table 270. Cannabinoid Drugs Synthetics , by Region USD Million (2022-2027)
  • Table 271. Cannabinoid Drugs: by Application(USD Million)
  • Table 272. Cannabinoid Drugs Chronic Diseases , by Region USD Million (2022-2027)
  • Table 273. Cannabinoid Drugs Anxiety , by Region USD Million (2022-2027)
  • Table 274. Cannabinoid Drugs Nausea , by Region USD Million (2022-2027)
  • Table 275. Cannabinoid Drugs Others , by Region USD Million (2022-2027)
  • Table 276. Cannabinoid Drugs: by End-users(USD Million)
  • Table 277. Cannabinoid Drugs Hospitals , by Region USD Million (2022-2027)
  • Table 278. Cannabinoid Drugs Clinics , by Region USD Million (2022-2027)
  • Table 279. Cannabinoid Drugs Ambulatory Surgical Centers , by Region USD Million (2022-2027)
  • Table 280. Cannabinoid Drugs Others , by Region USD Million (2022-2027)
  • Table 281. Cannabinoid Drugs: by Distribution Channel(USD Million)
  • Table 282. Cannabinoid Drugs Hospital Pharmacies , by Region USD Million (2022-2027)
  • Table 283. Cannabinoid Drugs Retail Pharmacies , by Region USD Million (2022-2027)
  • Table 284. Cannabinoid Drugs Online Pharmacies , by Region USD Million (2022-2027)
  • Table 285. South America Cannabinoid Drugs, by Country USD Million (2022-2027)
  • Table 286. South America Cannabinoid Drugs, by Type USD Million (2022-2027)
  • Table 287. South America Cannabinoid Drugs, by Application USD Million (2022-2027)
  • Table 288. South America Cannabinoid Drugs, by End-users USD Million (2022-2027)
  • Table 289. South America Cannabinoid Drugs, by Distribution Channel USD Million (2022-2027)
  • Table 290. Brazil Cannabinoid Drugs, by Type USD Million (2022-2027)
  • Table 291. Brazil Cannabinoid Drugs, by Application USD Million (2022-2027)
  • Table 292. Brazil Cannabinoid Drugs, by End-users USD Million (2022-2027)
  • Table 293. Brazil Cannabinoid Drugs, by Distribution Channel USD Million (2022-2027)
  • Table 294. Argentina Cannabinoid Drugs, by Type USD Million (2022-2027)
  • Table 295. Argentina Cannabinoid Drugs, by Application USD Million (2022-2027)
  • Table 296. Argentina Cannabinoid Drugs, by End-users USD Million (2022-2027)
  • Table 297. Argentina Cannabinoid Drugs, by Distribution Channel USD Million (2022-2027)
  • Table 298. Rest of South America Cannabinoid Drugs, by Type USD Million (2022-2027)
  • Table 299. Rest of South America Cannabinoid Drugs, by Application USD Million (2022-2027)
  • Table 300. Rest of South America Cannabinoid Drugs, by End-users USD Million (2022-2027)
  • Table 301. Rest of South America Cannabinoid Drugs, by Distribution Channel USD Million (2022-2027)
  • Table 302. Asia Pacific Cannabinoid Drugs, by Country USD Million (2022-2027)
  • Table 303. Asia Pacific Cannabinoid Drugs, by Type USD Million (2022-2027)
  • Table 304. Asia Pacific Cannabinoid Drugs, by Application USD Million (2022-2027)
  • Table 305. Asia Pacific Cannabinoid Drugs, by End-users USD Million (2022-2027)
  • Table 306. Asia Pacific Cannabinoid Drugs, by Distribution Channel USD Million (2022-2027)
  • Table 307. China Cannabinoid Drugs, by Type USD Million (2022-2027)
  • Table 308. China Cannabinoid Drugs, by Application USD Million (2022-2027)
  • Table 309. China Cannabinoid Drugs, by End-users USD Million (2022-2027)
  • Table 310. China Cannabinoid Drugs, by Distribution Channel USD Million (2022-2027)
  • Table 311. Japan Cannabinoid Drugs, by Type USD Million (2022-2027)
  • Table 312. Japan Cannabinoid Drugs, by Application USD Million (2022-2027)
  • Table 313. Japan Cannabinoid Drugs, by End-users USD Million (2022-2027)
  • Table 314. Japan Cannabinoid Drugs, by Distribution Channel USD Million (2022-2027)
  • Table 315. India Cannabinoid Drugs, by Type USD Million (2022-2027)
  • Table 316. India Cannabinoid Drugs, by Application USD Million (2022-2027)
  • Table 317. India Cannabinoid Drugs, by End-users USD Million (2022-2027)
  • Table 318. India Cannabinoid Drugs, by Distribution Channel USD Million (2022-2027)
  • Table 319. South Korea Cannabinoid Drugs, by Type USD Million (2022-2027)
  • Table 320. South Korea Cannabinoid Drugs, by Application USD Million (2022-2027)
  • Table 321. South Korea Cannabinoid Drugs, by End-users USD Million (2022-2027)
  • Table 322. South Korea Cannabinoid Drugs, by Distribution Channel USD Million (2022-2027)
  • Table 323. Taiwan Cannabinoid Drugs, by Type USD Million (2022-2027)
  • Table 324. Taiwan Cannabinoid Drugs, by Application USD Million (2022-2027)
  • Table 325. Taiwan Cannabinoid Drugs, by End-users USD Million (2022-2027)
  • Table 326. Taiwan Cannabinoid Drugs, by Distribution Channel USD Million (2022-2027)
  • Table 327. Australia Cannabinoid Drugs, by Type USD Million (2022-2027)
  • Table 328. Australia Cannabinoid Drugs, by Application USD Million (2022-2027)
  • Table 329. Australia Cannabinoid Drugs, by End-users USD Million (2022-2027)
  • Table 330. Australia Cannabinoid Drugs, by Distribution Channel USD Million (2022-2027)
  • Table 331. Rest of Asia-Pacific Cannabinoid Drugs, by Type USD Million (2022-2027)
  • Table 332. Rest of Asia-Pacific Cannabinoid Drugs, by Application USD Million (2022-2027)
  • Table 333. Rest of Asia-Pacific Cannabinoid Drugs, by End-users USD Million (2022-2027)
  • Table 334. Rest of Asia-Pacific Cannabinoid Drugs, by Distribution Channel USD Million (2022-2027)
  • Table 335. Europe Cannabinoid Drugs, by Country USD Million (2022-2027)
  • Table 336. Europe Cannabinoid Drugs, by Type USD Million (2022-2027)
  • Table 337. Europe Cannabinoid Drugs, by Application USD Million (2022-2027)
  • Table 338. Europe Cannabinoid Drugs, by End-users USD Million (2022-2027)
  • Table 339. Europe Cannabinoid Drugs, by Distribution Channel USD Million (2022-2027)
  • Table 340. Germany Cannabinoid Drugs, by Type USD Million (2022-2027)
  • Table 341. Germany Cannabinoid Drugs, by Application USD Million (2022-2027)
  • Table 342. Germany Cannabinoid Drugs, by End-users USD Million (2022-2027)
  • Table 343. Germany Cannabinoid Drugs, by Distribution Channel USD Million (2022-2027)
  • Table 344. France Cannabinoid Drugs, by Type USD Million (2022-2027)
  • Table 345. France Cannabinoid Drugs, by Application USD Million (2022-2027)
  • Table 346. France Cannabinoid Drugs, by End-users USD Million (2022-2027)
  • Table 347. France Cannabinoid Drugs, by Distribution Channel USD Million (2022-2027)
  • Table 348. Italy Cannabinoid Drugs, by Type USD Million (2022-2027)
  • Table 349. Italy Cannabinoid Drugs, by Application USD Million (2022-2027)
  • Table 350. Italy Cannabinoid Drugs, by End-users USD Million (2022-2027)
  • Table 351. Italy Cannabinoid Drugs, by Distribution Channel USD Million (2022-2027)
  • Table 352. United Kingdom Cannabinoid Drugs, by Type USD Million (2022-2027)
  • Table 353. United Kingdom Cannabinoid Drugs, by Application USD Million (2022-2027)
  • Table 354. United Kingdom Cannabinoid Drugs, by End-users USD Million (2022-2027)
  • Table 355. United Kingdom Cannabinoid Drugs, by Distribution Channel USD Million (2022-2027)
  • Table 356. Netherlands Cannabinoid Drugs, by Type USD Million (2022-2027)
  • Table 357. Netherlands Cannabinoid Drugs, by Application USD Million (2022-2027)
  • Table 358. Netherlands Cannabinoid Drugs, by End-users USD Million (2022-2027)
  • Table 359. Netherlands Cannabinoid Drugs, by Distribution Channel USD Million (2022-2027)
  • Table 360. Rest of Europe Cannabinoid Drugs, by Type USD Million (2022-2027)
  • Table 361. Rest of Europe Cannabinoid Drugs, by Application USD Million (2022-2027)
  • Table 362. Rest of Europe Cannabinoid Drugs, by End-users USD Million (2022-2027)
  • Table 363. Rest of Europe Cannabinoid Drugs, by Distribution Channel USD Million (2022-2027)
  • Table 364. MEA Cannabinoid Drugs, by Country USD Million (2022-2027)
  • Table 365. MEA Cannabinoid Drugs, by Type USD Million (2022-2027)
  • Table 366. MEA Cannabinoid Drugs, by Application USD Million (2022-2027)
  • Table 367. MEA Cannabinoid Drugs, by End-users USD Million (2022-2027)
  • Table 368. MEA Cannabinoid Drugs, by Distribution Channel USD Million (2022-2027)
  • Table 369. Middle East Cannabinoid Drugs, by Type USD Million (2022-2027)
  • Table 370. Middle East Cannabinoid Drugs, by Application USD Million (2022-2027)
  • Table 371. Middle East Cannabinoid Drugs, by End-users USD Million (2022-2027)
  • Table 372. Middle East Cannabinoid Drugs, by Distribution Channel USD Million (2022-2027)
  • Table 373. Africa Cannabinoid Drugs, by Type USD Million (2022-2027)
  • Table 374. Africa Cannabinoid Drugs, by Application USD Million (2022-2027)
  • Table 375. Africa Cannabinoid Drugs, by End-users USD Million (2022-2027)
  • Table 376. Africa Cannabinoid Drugs, by Distribution Channel USD Million (2022-2027)
  • Table 377. North America Cannabinoid Drugs, by Country USD Million (2022-2027)
  • Table 378. North America Cannabinoid Drugs, by Type USD Million (2022-2027)
  • Table 379. North America Cannabinoid Drugs, by Application USD Million (2022-2027)
  • Table 380. North America Cannabinoid Drugs, by End-users USD Million (2022-2027)
  • Table 381. North America Cannabinoid Drugs, by Distribution Channel USD Million (2022-2027)
  • Table 382. United States Cannabinoid Drugs, by Type USD Million (2022-2027)
  • Table 383. United States Cannabinoid Drugs, by Application USD Million (2022-2027)
  • Table 384. United States Cannabinoid Drugs, by End-users USD Million (2022-2027)
  • Table 385. United States Cannabinoid Drugs, by Distribution Channel USD Million (2022-2027)
  • Table 386. Canada Cannabinoid Drugs, by Type USD Million (2022-2027)
  • Table 387. Canada Cannabinoid Drugs, by Application USD Million (2022-2027)
  • Table 388. Canada Cannabinoid Drugs, by End-users USD Million (2022-2027)
  • Table 389. Canada Cannabinoid Drugs, by Distribution Channel USD Million (2022-2027)
  • Table 390. Mexico Cannabinoid Drugs, by Type USD Million (2022-2027)
  • Table 391. Mexico Cannabinoid Drugs, by Application USD Million (2022-2027)
  • Table 392. Mexico Cannabinoid Drugs, by End-users USD Million (2022-2027)
  • Table 393. Mexico Cannabinoid Drugs, by Distribution Channel USD Million (2022-2027)
  • Table 394. Cannabinoid Drugs Sales: by Type(K Units)
  • Table 395. Cannabinoid Drugs Sales Phytocannabinoids , by Region K Units (2022-2027)
  • Table 396. Cannabinoid Drugs Sales Endocannabinoids , by Region K Units (2022-2027)
  • Table 397. Cannabinoid Drugs Sales Synthetics , by Region K Units (2022-2027)
  • Table 398. Cannabinoid Drugs Sales: by Application(K Units)
  • Table 399. Cannabinoid Drugs Sales Chronic Diseases , by Region K Units (2022-2027)
  • Table 400. Cannabinoid Drugs Sales Anxiety , by Region K Units (2022-2027)
  • Table 401. Cannabinoid Drugs Sales Nausea , by Region K Units (2022-2027)
  • Table 402. Cannabinoid Drugs Sales Others , by Region K Units (2022-2027)
  • Table 403. Cannabinoid Drugs Sales: by End-users(K Units)
  • Table 404. Cannabinoid Drugs Sales Hospitals , by Region K Units (2022-2027)
  • Table 405. Cannabinoid Drugs Sales Clinics , by Region K Units (2022-2027)
  • Table 406. Cannabinoid Drugs Sales Ambulatory Surgical Centers , by Region K Units (2022-2027)
  • Table 407. Cannabinoid Drugs Sales Others , by Region K Units (2022-2027)
  • Table 408. Cannabinoid Drugs Sales: by Distribution Channel(K Units)
  • Table 409. Cannabinoid Drugs Sales Hospital Pharmacies , by Region K Units (2022-2027)
  • Table 410. Cannabinoid Drugs Sales Retail Pharmacies , by Region K Units (2022-2027)
  • Table 411. Cannabinoid Drugs Sales Online Pharmacies , by Region K Units (2022-2027)
  • Table 412. South America Cannabinoid Drugs Sales, by Country K Units (2022-2027)
  • Table 413. South America Cannabinoid Drugs Sales, by Type K Units (2022-2027)
  • Table 414. South America Cannabinoid Drugs Sales, by Application K Units (2022-2027)
  • Table 415. South America Cannabinoid Drugs Sales, by End-users K Units (2022-2027)
  • Table 416. South America Cannabinoid Drugs Sales, by Distribution Channel K Units (2022-2027)
  • Table 417. Brazil Cannabinoid Drugs Sales, by Type K Units (2022-2027)
  • Table 418. Brazil Cannabinoid Drugs Sales, by Application K Units (2022-2027)
  • Table 419. Brazil Cannabinoid Drugs Sales, by End-users K Units (2022-2027)
  • Table 420. Brazil Cannabinoid Drugs Sales, by Distribution Channel K Units (2022-2027)
  • Table 421. Argentina Cannabinoid Drugs Sales, by Type K Units (2022-2027)
  • Table 422. Argentina Cannabinoid Drugs Sales, by Application K Units (2022-2027)
  • Table 423. Argentina Cannabinoid Drugs Sales, by End-users K Units (2022-2027)
  • Table 424. Argentina Cannabinoid Drugs Sales, by Distribution Channel K Units (2022-2027)
  • Table 425. Rest of South America Cannabinoid Drugs Sales, by Type K Units (2022-2027)
  • Table 426. Rest of South America Cannabinoid Drugs Sales, by Application K Units (2022-2027)
  • Table 427. Rest of South America Cannabinoid Drugs Sales, by End-users K Units (2022-2027)
  • Table 428. Rest of South America Cannabinoid Drugs Sales, by Distribution Channel K Units (2022-2027)
  • Table 429. Asia Pacific Cannabinoid Drugs Sales, by Country K Units (2022-2027)
  • Table 430. Asia Pacific Cannabinoid Drugs Sales, by Type K Units (2022-2027)
  • Table 431. Asia Pacific Cannabinoid Drugs Sales, by Application K Units (2022-2027)
  • Table 432. Asia Pacific Cannabinoid Drugs Sales, by End-users K Units (2022-2027)
  • Table 433. Asia Pacific Cannabinoid Drugs Sales, by Distribution Channel K Units (2022-2027)
  • Table 434. China Cannabinoid Drugs Sales, by Type K Units (2022-2027)
  • Table 435. China Cannabinoid Drugs Sales, by Application K Units (2022-2027)
  • Table 436. China Cannabinoid Drugs Sales, by End-users K Units (2022-2027)
  • Table 437. China Cannabinoid Drugs Sales, by Distribution Channel K Units (2022-2027)
  • Table 438. Japan Cannabinoid Drugs Sales, by Type K Units (2022-2027)
  • Table 439. Japan Cannabinoid Drugs Sales, by Application K Units (2022-2027)
  • Table 440. Japan Cannabinoid Drugs Sales, by End-users K Units (2022-2027)
  • Table 441. Japan Cannabinoid Drugs Sales, by Distribution Channel K Units (2022-2027)
  • Table 442. India Cannabinoid Drugs Sales, by Type K Units (2022-2027)
  • Table 443. India Cannabinoid Drugs Sales, by Application K Units (2022-2027)
  • Table 444. India Cannabinoid Drugs Sales, by End-users K Units (2022-2027)
  • Table 445. India Cannabinoid Drugs Sales, by Distribution Channel K Units (2022-2027)
  • Table 446. South Korea Cannabinoid Drugs Sales, by Type K Units (2022-2027)
  • Table 447. South Korea Cannabinoid Drugs Sales, by Application K Units (2022-2027)
  • Table 448. South Korea Cannabinoid Drugs Sales, by End-users K Units (2022-2027)
  • Table 449. South Korea Cannabinoid Drugs Sales, by Distribution Channel K Units (2022-2027)
  • Table 450. Taiwan Cannabinoid Drugs Sales, by Type K Units (2022-2027)
  • Table 451. Taiwan Cannabinoid Drugs Sales, by Application K Units (2022-2027)
  • Table 452. Taiwan Cannabinoid Drugs Sales, by End-users K Units (2022-2027)
  • Table 453. Taiwan Cannabinoid Drugs Sales, by Distribution Channel K Units (2022-2027)
  • Table 454. Australia Cannabinoid Drugs Sales, by Type K Units (2022-2027)
  • Table 455. Australia Cannabinoid Drugs Sales, by Application K Units (2022-2027)
  • Table 456. Australia Cannabinoid Drugs Sales, by End-users K Units (2022-2027)
  • Table 457. Australia Cannabinoid Drugs Sales, by Distribution Channel K Units (2022-2027)
  • Table 458. Rest of Asia-Pacific Cannabinoid Drugs Sales, by Type K Units (2022-2027)
  • Table 459. Rest of Asia-Pacific Cannabinoid Drugs Sales, by Application K Units (2022-2027)
  • Table 460. Rest of Asia-Pacific Cannabinoid Drugs Sales, by End-users K Units (2022-2027)
  • Table 461. Rest of Asia-Pacific Cannabinoid Drugs Sales, by Distribution Channel K Units (2022-2027)
  • Table 462. Europe Cannabinoid Drugs Sales, by Country K Units (2022-2027)
  • Table 463. Europe Cannabinoid Drugs Sales, by Type K Units (2022-2027)
  • Table 464. Europe Cannabinoid Drugs Sales, by Application K Units (2022-2027)
  • Table 465. Europe Cannabinoid Drugs Sales, by End-users K Units (2022-2027)
  • Table 466. Europe Cannabinoid Drugs Sales, by Distribution Channel K Units (2022-2027)
  • Table 467. Germany Cannabinoid Drugs Sales, by Type K Units (2022-2027)
  • Table 468. Germany Cannabinoid Drugs Sales, by Application K Units (2022-2027)
  • Table 469. Germany Cannabinoid Drugs Sales, by End-users K Units (2022-2027)
  • Table 470. Germany Cannabinoid Drugs Sales, by Distribution Channel K Units (2022-2027)
  • Table 471. France Cannabinoid Drugs Sales, by Type K Units (2022-2027)
  • Table 472. France Cannabinoid Drugs Sales, by Application K Units (2022-2027)
  • Table 473. France Cannabinoid Drugs Sales, by End-users K Units (2022-2027)
  • Table 474. France Cannabinoid Drugs Sales, by Distribution Channel K Units (2022-2027)
  • Table 475. Italy Cannabinoid Drugs Sales, by Type K Units (2022-2027)
  • Table 476. Italy Cannabinoid Drugs Sales, by Application K Units (2022-2027)
  • Table 477. Italy Cannabinoid Drugs Sales, by End-users K Units (2022-2027)
  • Table 478. Italy Cannabinoid Drugs Sales, by Distribution Channel K Units (2022-2027)
  • Table 479. United Kingdom Cannabinoid Drugs Sales, by Type K Units (2022-2027)
  • Table 480. United Kingdom Cannabinoid Drugs Sales, by Application K Units (2022-2027)
  • Table 481. United Kingdom Cannabinoid Drugs Sales, by End-users K Units (2022-2027)
  • Table 482. United Kingdom Cannabinoid Drugs Sales, by Distribution Channel K Units (2022-2027)
  • Table 483. Netherlands Cannabinoid Drugs Sales, by Type K Units (2022-2027)
  • Table 484. Netherlands Cannabinoid Drugs Sales, by Application K Units (2022-2027)
  • Table 485. Netherlands Cannabinoid Drugs Sales, by End-users K Units (2022-2027)
  • Table 486. Netherlands Cannabinoid Drugs Sales, by Distribution Channel K Units (2022-2027)
  • Table 487. Rest of Europe Cannabinoid Drugs Sales, by Type K Units (2022-2027)
  • Table 488. Rest of Europe Cannabinoid Drugs Sales, by Application K Units (2022-2027)
  • Table 489. Rest of Europe Cannabinoid Drugs Sales, by End-users K Units (2022-2027)
  • Table 490. Rest of Europe Cannabinoid Drugs Sales, by Distribution Channel K Units (2022-2027)
  • Table 491. MEA Cannabinoid Drugs Sales, by Country K Units (2022-2027)
  • Table 492. MEA Cannabinoid Drugs Sales, by Type K Units (2022-2027)
  • Table 493. MEA Cannabinoid Drugs Sales, by Application K Units (2022-2027)
  • Table 494. MEA Cannabinoid Drugs Sales, by End-users K Units (2022-2027)
  • Table 495. MEA Cannabinoid Drugs Sales, by Distribution Channel K Units (2022-2027)
  • Table 496. Middle East Cannabinoid Drugs Sales, by Type K Units (2022-2027)
  • Table 497. Middle East Cannabinoid Drugs Sales, by Application K Units (2022-2027)
  • Table 498. Middle East Cannabinoid Drugs Sales, by End-users K Units (2022-2027)
  • Table 499. Middle East Cannabinoid Drugs Sales, by Distribution Channel K Units (2022-2027)
  • Table 500. Africa Cannabinoid Drugs Sales, by Type K Units (2022-2027)
  • Table 501. Africa Cannabinoid Drugs Sales, by Application K Units (2022-2027)
  • Table 502. Africa Cannabinoid Drugs Sales, by End-users K Units (2022-2027)
  • Table 503. Africa Cannabinoid Drugs Sales, by Distribution Channel K Units (2022-2027)
  • Table 504. North America Cannabinoid Drugs Sales, by Country K Units (2022-2027)
  • Table 505. North America Cannabinoid Drugs Sales, by Type K Units (2022-2027)
  • Table 506. North America Cannabinoid Drugs Sales, by Application K Units (2022-2027)
  • Table 507. North America Cannabinoid Drugs Sales, by End-users K Units (2022-2027)
  • Table 508. North America Cannabinoid Drugs Sales, by Distribution Channel K Units (2022-2027)
  • Table 509. United States Cannabinoid Drugs Sales, by Type K Units (2022-2027)
  • Table 510. United States Cannabinoid Drugs Sales, by Application K Units (2022-2027)
  • Table 511. United States Cannabinoid Drugs Sales, by End-users K Units (2022-2027)
  • Table 512. United States Cannabinoid Drugs Sales, by Distribution Channel K Units (2022-2027)
  • Table 513. Canada Cannabinoid Drugs Sales, by Type K Units (2022-2027)
  • Table 514. Canada Cannabinoid Drugs Sales, by Application K Units (2022-2027)
  • Table 515. Canada Cannabinoid Drugs Sales, by End-users K Units (2022-2027)
  • Table 516. Canada Cannabinoid Drugs Sales, by Distribution Channel K Units (2022-2027)
  • Table 517. Mexico Cannabinoid Drugs Sales, by Type K Units (2022-2027)
  • Table 518. Mexico Cannabinoid Drugs Sales, by Application K Units (2022-2027)
  • Table 519. Mexico Cannabinoid Drugs Sales, by End-users K Units (2022-2027)
  • Table 520. Mexico Cannabinoid Drugs Sales, by Distribution Channel K Units (2022-2027)
  • Table 521. Cannabinoid Drugs: by Type(USD/Units)
  • Table 522. Research Programs/Design for This Report
  • Table 523. Key Data Information from Secondary Sources
  • Table 524. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Cannabinoid Drugs: by Type USD Million (2016-2021)
  • Figure 5. Global Cannabinoid Drugs: by Application USD Million (2016-2021)
  • Figure 6. Global Cannabinoid Drugs: by End-users USD Million (2016-2021)
  • Figure 7. Global Cannabinoid Drugs: by Distribution Channel USD Million (2016-2021)
  • Figure 8. South America Cannabinoid Drugs Share (%), by Country
  • Figure 9. Asia Pacific Cannabinoid Drugs Share (%), by Country
  • Figure 10. Europe Cannabinoid Drugs Share (%), by Country
  • Figure 11. MEA Cannabinoid Drugs Share (%), by Country
  • Figure 12. North America Cannabinoid Drugs Share (%), by Country
  • Figure 13. Global Cannabinoid Drugs: by Type K Units (2016-2021)
  • Figure 14. Global Cannabinoid Drugs: by Application K Units (2016-2021)
  • Figure 15. Global Cannabinoid Drugs: by End-users K Units (2016-2021)
  • Figure 16. Global Cannabinoid Drugs: by Distribution Channel K Units (2016-2021)
  • Figure 17. South America Cannabinoid Drugs Share (%), by Country
  • Figure 18. Asia Pacific Cannabinoid Drugs Share (%), by Country
  • Figure 19. Europe Cannabinoid Drugs Share (%), by Country
  • Figure 20. MEA Cannabinoid Drugs Share (%), by Country
  • Figure 21. North America Cannabinoid Drugs Share (%), by Country
  • Figure 22. Global Cannabinoid Drugs: by Type USD/Units (2016-2021)
  • Figure 23. Global Cannabinoid Drugs share by Players 2021 (%)
  • Figure 24. Global Cannabinoid Drugs share by Players (Top 3) 2021(%)
  • Figure 25. Global Cannabinoid Drugs share by Players (Top 5) 2021(%)
  • Figure 26. BCG Matrix for key Companies
  • Figure 27. Echo Pharmaceuticals B.V. (Netherlands) Revenue, Net Income and Gross profit
  • Figure 28. Echo Pharmaceuticals B.V. (Netherlands) Revenue: by Geography 2021
  • Figure 29. Mandara Pharma (Canada) Revenue, Net Income and Gross profit
  • Figure 30. Mandara Pharma (Canada) Revenue: by Geography 2021
  • Figure 31. GW Pharmaceuticals, plc (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 32. GW Pharmaceuticals, plc (United Kingdom) Revenue: by Geography 2021
  • Figure 33. Nexien BioPharma (United States) Revenue, Net Income and Gross profit
  • Figure 34. Nexien BioPharma (United States) Revenue: by Geography 2021
  • Figure 35. BOL Pharma (Israel) Revenue, Net Income and Gross profit
  • Figure 36. BOL Pharma (Israel) Revenue: by Geography 2021
  • Figure 37. CURE Pharmaceutical Holding Corp. (United States) Revenue, Net Income and Gross profit
  • Figure 38. CURE Pharmaceutical Holding Corp. (United States) Revenue: by Geography 2021
  • Figure 39. RAMM Pharma (Canada) Revenue, Net Income and Gross profit
  • Figure 40. RAMM Pharma (Canada) Revenue: by Geography 2021
  • Figure 41. Greenwich Biosciences, Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 42. Greenwich Biosciences, Inc. (United States) Revenue: by Geography 2021
  • Figure 43. UNIVO Pharmaceuticals (Israel) Revenue, Net Income and Gross profit
  • Figure 44. UNIVO Pharmaceuticals (Israel) Revenue: by Geography 2021
  • Figure 45. InMed Pharmaceuticals (Canada) Revenue, Net Income and Gross profit
  • Figure 46. InMed Pharmaceuticals (Canada) Revenue: by Geography 2021
  • Figure 47. Abbott Laboratories (United States) Revenue, Net Income and Gross profit
  • Figure 48. Abbott Laboratories (United States) Revenue: by Geography 2021
  • Figure 49. Global Cannabinoid Drugs: by Type USD Million (2022-2027)
  • Figure 50. Global Cannabinoid Drugs: by Application USD Million (2022-2027)
  • Figure 51. Global Cannabinoid Drugs: by End-users USD Million (2022-2027)
  • Figure 52. Global Cannabinoid Drugs: by Distribution Channel USD Million (2022-2027)
  • Figure 53. South America Cannabinoid Drugs Share (%), by Country
  • Figure 54. Asia Pacific Cannabinoid Drugs Share (%), by Country
  • Figure 55. Europe Cannabinoid Drugs Share (%), by Country
  • Figure 56. MEA Cannabinoid Drugs Share (%), by Country
  • Figure 57. North America Cannabinoid Drugs Share (%), by Country
  • Figure 58. Global Cannabinoid Drugs: by Type K Units (2022-2027)
  • Figure 59. Global Cannabinoid Drugs: by Application K Units (2022-2027)
  • Figure 60. Global Cannabinoid Drugs: by End-users K Units (2022-2027)
  • Figure 61. Global Cannabinoid Drugs: by Distribution Channel K Units (2022-2027)
  • Figure 62. South America Cannabinoid Drugs Share (%), by Country
  • Figure 63. Asia Pacific Cannabinoid Drugs Share (%), by Country
  • Figure 64. Europe Cannabinoid Drugs Share (%), by Country
  • Figure 65. MEA Cannabinoid Drugs Share (%), by Country
  • Figure 66. North America Cannabinoid Drugs Share (%), by Country
  • Figure 67. Global Cannabinoid Drugs: by Type USD/Units (2022-2027)
List of companies from research coverage that are profiled in the study
  • Echo Pharmaceuticals B.V. (Netherlands)
  • Mandara Pharma (Canada)
  • GW Pharmaceuticals, plc (United Kingdom)
  • Nexien BioPharma (United States)
  • BOL Pharma (Israel)
  • CURE Pharmaceutical Holding Corp. (United States)
  • RAMM Pharma (Canada)
  • Greenwich Biosciences, Inc. (United States)
  • UNIVO Pharmaceuticals (Israel)
  • InMed Pharmaceuticals (Canada)
  • Abbott Laboratories (United States)
Additional players considered in the study are as follows:
Ilesol Pharmaceuticals d.o.o. (Croatia) , Valeant Pharmaceuticals International (Canada) , Indevus Pharmaceuticals Inc. (United States)
Select User Access Type

Key Highlights of Report


Feb 2022 204 Pages 63 Tables Base Year: 2021 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Global Cannabinoid Drugs Market Quantitative research analysis
Global Cannabinoid Drugs Market Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

"Increasing Prevalence of Chronic Diseases " is seen as one of major growth factors of Cannabinoid Drugs Market in years to come.
The Study can be customized subject to feasibility and data availability. Please connect with our sales representative for further information.
United States will lead Cannabinoid Drugs Market in coming years.

Know More About Global Cannabinoid Drugs Market Report?

Have a Query? Click Here

Other Related Reports

Epileptic Seizures Treatment Comprehensive Study by Type (Convulsive Status Epilepticus, Non-Convulsive Status Epilepticus), Therapeutic (Midazolam, Alprazolam, Diazepam, Phenytoin, Fosphenytoin, Ot...
$ 3650
Erythropoiesis Stimulating Agents Comprehensive Study by Type (Epoetin Alfa, Epoetin Beta, Epoetin Omega, Epoetin Delta, Darbepoetin Alfa), Application (Cancer, Renal Disorders, Anti-retroviral Treat...
$ 3650
Chemotherapy Drugs Comprehensive Study by Type (Alkylating Agents, Antitumor Antibiotics, Plant Alkaloids, Antimetabolites, Topoisomerase Inhibitors, Miscellaneous Antineoplastic), Route of Administr...
$ 3750
Neurofibromatosis Treatment Drugs Comprehensive Study by Type (Selumetinib, Bevacizumab, Koselugo), Application (Clinic, Hospital, Home Care), Distribution Channel (Online, Offline), Neurofibromas (C...
$ 3350
CBD Oil Extract Comprehensive Study by Application (Medical, Personal Use, Pharmaceutical, Wellness), Source (Hemp, Marijuana) Players and Region - Global Market Outlook to 2026
$ 3500
Quit Smoking Drug Comprehensive Study by Type (Chewing Gum, Inhaler, Lozenge, Patch, Spray, Sublingual Tablets), Application (Hospital, Medical Center), Distribution Channel (Hospitals Pharmacies, Dr...
$ 3650